Bringing science and development together through news and analysis

EU approves US$947 million for African clinical trials
  • EU approves US$947 million for African clinical trials

Copyright: European Parliament

Speed read

  • The proposed budget received approval from 642 out of 647 eligible voters

  • The funding will aid clinical trials for HIV/AIDS, malaria and other diseases

  • An expert says it could help strengthen research systems

Shares
[CAPE TOWN]  The European Council has approved a 683 million euro (US$947 million) budget proposal for the second phase of the European and Developing Countries Clinical Trials Partnership (EDCTP2) to boost medical research in Sub-Saharan Africa.
 
The new budget passed by the council of the European Commission today (May 6) triples that of the first phase (2003-2015) which was US$278 million. The new funding is part of Horizon 2020, the EU Framework Programme for Research and Innovation 2014-2020.
 
The European Parliament approved the proposed budget with overwhelming majority of 646 out of 671 votes last month (15 April) and was awaiting the council’s vote.

“The larger budget demonstrates a widely shared confidence that the second EDCTP programme will deliver on its promise.”

Charles Mgone, The European and Developing Countries Clinical Trials Partnership (EDCTP)


The EDCTP works to establish and strengthen research capacity in 48 countries in Sub-Saharan Africa to accelerate clinical trials to produce new drugs for combating HIV/AIDS, malaria and tuberculosis in Sub-Saharan African.
 
Charles Mgone, EDCTP executive director, says more funding will translate into more support for a larger number of projects and clinical trials.
 
“This action reflects the importance that the European Union attaches to its partnership with Africa and to the fight against poverty-related diseases as well as recognition of the very tangible results of the first EDCTP programme as an instrument for achieving these aims,” he says.
 
Mgone adds: “The larger budget demonstrates a widely shared confidence that the second EDCTP programme will deliver on its promise”. 
 
He tells SciDev.Net that provision of facilities for study sites and research centres will take place on a larger scale, accommodating a bigger number of African researchers.
 
Renate Baehr, executive director of Germany-headquartered Deutsche Stiftung Weltbevoelkerung, an international development organisation, says that the EDCTP2 can build on the success in raising awareness on the value of research and development for global health in Sub-Saharan Africa of the first phase.
 
“It sends out an important signal ahead of the negotiations on the post-2015 development agenda that in order to tackle the still crippling effects of poverty-related and neglected diseases, investment in research and development, and innovation for global health is crucial,” Baehr tells SciDev.Net.
 
According to Mgone EDCTP2 will expand to include all phases of clinical trials as well as implementation research for HIV/AIDS, tuberculosis, malaria, neglected infectious diseases, and possibly diarrhoeal and respiratory infections.
 
“The [funded] research will cover areas such as implementation research which provides evidence to optimize the usage of evidence to support provision of improved health services,” says Modest Mulenga, director, Tropical Diseases Research Centre, Ndola, Zambia. “This is a unique aspect of EDCTP2.”
 
Gibson Kibiki, director, Kilimanjaro Clinical Research Institute in Tanzania, says after building capacity, which allows his outfit to function properly, the second phase will be geared more towards strengthening the systems and structures.
 
“We will use the available resources for training, and to decrease dependency on our northern partners in processing research specimens,” Kibiki tells SciDev.Net.
 
This article has been produced by SciDev.Net's Sub-Saharan Africa desk.
Republish
We encourage you to republish this article online and in print, it’s free under our creative commons attribution license, but please follow some simple guidelines:
  1. You have to credit our authors.
  2. You have to credit SciDev.Net — where possible include our logo with a link back to the original article.
  3. You can simply run the first few lines of the article and then add: “Read the full article on SciDev.Net” containing a link back to the original article.
  4. If you want to also take images published in this story you will need to confirm with the original source if you're licensed to use them.
  5. The easiest way to get the article on your site is to embed the code below.
For more information view our media page and republishing guidelines.